Supernus at Citibank and RBC Global Healthcare Conferences in February
ROCKVILLE, Md. -- February 7, 2014
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical
company, today announced that the Company’s management will be hosting
investor meetings during Citi’s 2014 Global Healthcare Conference.
Date: Tuesday, February 25
Place: The Hilton New York Hotel
Investors interested in arranging a meeting during this conference should
contact their Citi representative.
Supernus also announced that management will provide a business update on the
Company at the 2014 RBC Capital Markets Global Healthcare Conference.
Date: Wednesday, February 26
Presentation Time: 9:00am ET
Place: The New York Palace, New York, NY
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused
on developing and commercializing products for the treatment of central
nervous system, or CNS, diseases. The Company has two marketed products for
epilepsy, Oxtellar XR® (extended-release oxcarbazepine) and Trokendi XR™
(extended-release topiramate). The Company is also developing several product
candidates in psychiatry to address large market opportunities in ADHD,
including ADHD patients with impulsive aggression. These product candidates
include SPN-810 for impulsive aggression in ADHD and SPN-812 for ADHD.
Supernus Pharmaceuticals, Inc.
Jack A. Khattar, President and CEO
Gregory S. Patrick, Vice President and CFO
Press spacebar to pause and continue. Press esc to stop.